SCHEMBL4512153

SCHEMBL4512153

Clc1ccc(CCBr)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8671567 0.85 MMP8 (0.46)
SCHEMBL10684316 0.82 TDP1 (0.39)
SCHEMBL1372325 0.80
SCHEMBL5542040 0.76
SCHEMBL4526544 0.76
SCHEMBL9510741 0.74 MMP8 (0.33)
SCHEMBL10929660 0.74 MMP8 (0.38)
SCHEMBL4104800 0.73
SCHEMBL6637599 0.73 MMP8 (0.39)
SCHEMBL190205 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12251373-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2025-03-18 US disclosed
US-20240041847-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION UNIV CASE WESTERN RESERVE (US) 2024-02-08 US disclosed
US-11744826-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2023-09-05 US disclosed
US-20220087992-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
US-11191752-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2021-12-07 US disclosed
US-20200230119-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION CASE WESTERN RESERVE UNIVERSITY 2020-07-23 US disclosed
EP-3486231-A1 PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-05-22 EP disclosed
US-7482374-B2 Pyrrolidine-2-ones as Factor Xa inhibitors GLAXO GROUP LIMITED (GB) 2009-01-27 US disclosed
US-7482374-B2 Pyrrolidine-2-ones as Factor Xa inhibitors GLAXO GROUP LIMITED (GB) 2009-01-27 US disclosed
US-7482374-B2 Pyrrolidine-2-ones as Factor Xa inhibitors GLAXO GROUP LIMITED (GB) 2009-01-27 US disclosed
EP-1641786-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2006-04-05 EP disclosed
EP-1567489-A1 PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
US-20050059726-A1 Pyrrolidine-2-ones as factor xa inhibitors GLAXO GROUP LIMITED (GB) 2005-03-17 US disclosed
WO-2004111045-A1 PYRROLIDINE - 2- ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-23 WO disclosed
WO-2004111045-A1 PYRROLIDINE - 2- ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-23 WO disclosed
CN-1167687-C Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors ���Ͽع����޹�˾ 2004-09-22 CN disclosed
EP-1456172-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2004-09-15 EP disclosed
WO-2004052851-A1 PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA GLAXO GROUP LIMITED (GB) 2004-06-24 WO disclosed
WO-2003053925-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed
CN-1277605-A Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors ABBOTT LAB (US) 2000-12-20 CN disclosed